LTF and COVID-19: In addition to its oral bioavailability, the lack of immunogenicity, and the broad-spectrum antiviral activity, lactoferrin has also shown anti-inflammatory and immunomodulatory activities in severe viral infections [196], thus resulting in a promising drug candidate for COVID-19.